| Израиль | Түркия | Австрия | |
| Сүт безі рагында химиотерапия | бастап $22,500 | бастап $1,200 | бастап $15,000 |
| Сүйек деформациясын түзету операциясы | бастап $13,800 | бастап $2,500 | бастап $30,000 |
| Тік ішек қатерлі ісігінде сәулелік терапия | - | бастап $7,000 | бастап $12,000 |
| Сүйекті резекциялау | - | бастап $8,000 | бастап $25,000 |
| Актиний-225 терапиясы | - | бастап $22,955 | бастап $55,000 |
Клиника Ассута (Assuta) — Израильдегі ең ірі жеке медициналық орталық. Госпиталь онкология, ортопедия, нейро-, кардиохирургия және бедеулікті емдеуге маманданған. Елдегі барлық операциялардың 13% Ассутада өткізіледі, бұл оны хирургия бойынша жетекші орталық етеді.
Емдеудің сапасы мен қауіпсіздігі үшін аурухана американдық Joint Commission International аккредитациясын алды.
Әр жыл сайын Ассута желісінің дәрігерлері 92 000-нан астам операция, 685 000 диагностикалық процедура және 16 000 ЭКО циклдарын өткізеді.
Сураски медициналық орталығындағы Жұмсақ тіндер мен сүйек онкологиясы бөлімінің жетекшісі — тек саркома жағдайларын емдеуге маманданған.
Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.
He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.
He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.
Доктор Дрор Левин — Тель-Авивтегі Сураски медициналық орталығының балалардағы сүйек қатерлі ісігін (саркома) емдеу жөніндегі жетекші маманы.
Доктор Бикельс озық ортопедиялық онкология саласында маманданған және Сураски медициналық орталығындағы сүйектің метастаздық зақымдануын емдеудің бірегей бөлімшесін басқарады.
Bone cancer treatment in Israel is exceptionally safe. Highly qualified specialists operate within JCI-accredited facilities using advanced limb-sparing protocols. Major centers like Sourasky report a 90% average success rate for oncology. Surgeons frequently hold fellowships from elite global institutions like Harvard and Rizzoli.
Bookimed Expert Insight: Israeli oncology centers like Sourasky and Sheba function as massive hubs, serving up to 2 million patients annually. This volume creates a unique data advantage. Specialists like Dr. Eytan Aharon Ben-ami leverage this by leading Phase I clinical trials in immunotherapy. Choosing a high-volume public facility often provides better access to these newer protocols than smaller private clinics.
Patient Consensus: Patients note that care coordination is a major strength in Israel. They emphasize the peace of mind found in specialized orthopedic oncology departments rather than general surgical wards.
Israel treats bone cancer using precision technologies like 3D-printed biocompatible bone implants and remote-controlled telescopic endoprostheses for children. Specialized centers employ navigation-assisted surgery and Actinium-225 therapy to target tumors. High-volume hospitals use CAR-T cell therapy and magnetic nanoparticles for resistant cases.
Bookimed Expert Insight: Israeli oncology centers like Sheba and Sourasky operate as massive research hubs, serving over 1,000,000 patients each annually. This scale allows them to offer specialized units for specific conditions, such as the National Center for bone and soft tissues sarcomas. For patients, this means accessing doctors like Dr. Eytan Aharon Ben-ami who exclusively manage rare sarcomas rather than general orthopedics.
Patient Consensus: Patients note that centers prioritize neoadjuvant chemotherapy to shrink tumors before attempting limb-salvage surgery. Families often emphasize the value of 3D-guided planning for complex cases to ensure precise tumor removal.
Israeli oncology centers report an average success rate of 90% for bone cancer treatments. Five-year survival for localized bone sarcoma reaches approximately 83%. Advanced centers specialize in limb-sparing surgeries. These procedures successfully preserve limbs in 90% of cases without requiring amputation.
Bookimed Expert Insight: Israeli oncology leads in survival due to highly specialized sub-divisions. For example, Sourasky Medical Center maintains separate units for metastatic lesions and pediatric sarcomas. Dr. Ofer Merimsky and Dr. Dror Levin head these specific areas. This granular expertise allows for personalized protocols that general oncology departments cannot match.
Patient Consensus: Patients emphasize that early detection is the most critical factor for a 60-80% survival chance. Many note that choosing limb-sparing surgery over amputation requires a careful discussion about long-term function and recovery.
Recovery in Israel involves immediate orthopedic rehabilitation starting within 24–48 hours after surgery. Multidisciplinary teams at JCI-accredited centers like Sourasky (Ichilov) and Sheba focus on mobility using hydrotherapy and motion analysis labs. Specialized protocols aim to restore functionality while preserving the limb and managing pain.
Bookimed Expert Insight: While many focus on the surgery itself, the 90% oncology success rate at Sourasky Medical Center is heavily supported by their specialized sarcoma units. These departments, led by experts like Dr. Ofer Merimsky and Dr. Jakov Bikels, integrate surgical planning directly with long-term rehab. Data shows that clinics with high annual volumes, like Sheba's 45,000+ operations, often provide more robust motion analysis technology that helps fine-tune gait earlier in the recovery process.
Patient Consensus: Patients emphasize that rehabilitation is a long-term commitment, often noting that regaining full independence takes about a year. Many highlight the value of specialized support groups to manage the emotional challenges during the months of intensive physical therapy.
International patients usually stay in Israel for 3 to 12 weeks for bone cancer treatment. This duration covers diagnosis, limb-salvage surgery, and initial recovery. Complete oncology protocols including chemotherapy may last 6 to 9 months. Patients often follow these long-term regimens in their home countries.
Bookimed Expert Insight: Israeli oncology centers like Sourasky Medical Center report survival success rates around 90%. Large tertiary centers often coordinate pediatric and orthopedic oncology as a joint plan. This efficiency can reduce the diagnostic phase to under 5 days. For long stays, patients should prioritize clinics in Tel Aviv or Ramat Gan for better long-term rental availability.
Patient Consensus: Patients emphasize planning a 2-week buffer for potential wound healing or implant delays. Many suggest booking flexible accommodation like apartments near the hospital for stays exceeding one month.
Amputation is no longer the standard of care for bone tumors in Israel. Surgeons now achieve limb-salvage rates of 90% to 95% for extremity cancers. Advanced techniques in reconstruction and chemotherapy preserve function. Precision imaging helps Israeli specialists remove tumors while protecting vital nerves and vessels.
Bookimed Expert Insight: Israeli oncology centers like Sourasky and Sheba prioritize multi-disciplinary tumor boards for every case. Our data shows that top specialists often hold international fellowships from institutions like Harvard. This global training allows them to offer early-phase clinical trials and immunotherapy. Dr. Eytan Ben-Ami at Sheba, for example, integrates targeted therapies that can shrink tumors and make limb-sparing surgery possible when others might suggest amputation.
Patient Consensus: Patients note that Israeli doctors focus heavily on maintaining mobility and quality of life. Many emphasize that the detailed pre-surgery imaging gave them confidence in avoiding amputation.
Tel Aviv, Jerusalem, and Ramat Gan are the primary hubs for international patients. These cities host facilities with Joint Commission International accreditation. They specialize in limb-sparing surgeries and complex sarcoma management. Specialists utilize advanced diagnostics like PET-CT and scintigraphy for precise staging.
Bookimed Expert Insight: While many choose Tel Aviv for its high volume, Ramat Gan stands out for multidisciplinary depth. Sheba Medical Center leverages ranking as a top global hospital to attract complex sarcoma cases. Sourasky in Tel Aviv maintains a 90% average oncology success rate across 240 departments. Choosing between these cities often depends on whether you need pediatric focus or adult surgical specialization.
Patient Consensus: Patients often mention the comfort of having English-speaking staff in Tel Aviv clinics. They also highlight that centers in Jerusalem provide a very supportive environment for families during long treatments.